[Singapore / Oxford – 13th June 2025]
Credence Genomics, an innovator in NGS-based pathogen detection, and Oxford Nanopore Technologies, the global company behind a new generation of nanopore-based molecular sensing technology, today announced a strategic global partnership covering over 60 countries to drive accessibility for rapid detection of infectious disease. The collaboration will integrate Oxford Nanopore’s portable, high-throughput sequencing platforms with Credence’s proprietary CE-IVDR-certified diagnostic solutions—Bactfast®️, Virfast®️, Fungifast®️, and digitalABST®️—to enable near-care, rapid pathogen identification and digital antimicrobial susceptibility testing (AST).
Conventional and point-of-care (PoC) testing often produce delayed or inconclusive results, hampering timely clinical decisions. Credence intends to reduce this lag while providing clearer insights, employing a multi-sample, multi-pathogen protocol. This approach offers definitive, sequence-based identification and resistance profiling, addressing urgent global health needs such as sepsis management, antimicrobial resistance (AMR), and biosecurity preparedness.
The collaboration will focus on rapid, agnostic identification of infectious disease, detecting bacteria, viruses, and fungi in a single streamlined workflow. It intends to deliver scalable deployment, making high-accuracy sequencing available in decentralised, near-care settings. Simultaneously, it will drive access to this technology by providing actionable genomic insights at a cost comparable to legacy tests.
Dr. Vaz Gnanam, CEO of Credence Genomics, said:
“We see this collaboration as a symbiotic partnership to deliver life-saving, cost-effective pathogen identification using ONT’s robust sequencing platforms. Together, we believe this disruption will save lives and contribute significantly to addressing global challenges like sepsis and AMR.”
Gordon Sanghera, CEO of Oxford Nanopore, added:
“This collaboration exemplifies the future of infectious disease detection, combining Credence’s innovation with the flexibility and power of Oxford Nanopore’s sequencing technology. Together, we’re enabling rapid insights that can be deployed at the point of need. Our work the right information, in the right hands, at the right time.”
